Genzyme Corporation Product Pipeline Analysis

SUMMARY

Genzyme Corporation Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Genzyme Corporation's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Company Snapshot 9
2.1 Key Information 9
2.2 Company Overview 9
2.3 Financial Performance 9
2.4 Industry Outlook -- Orthopedic Devices 9
2.5 Industry Outlook -- In Vitro Diagnostics 10
3 Business Description 11
3.1 Business Overview 11
3.2 Major Products and Services 11
3.2.1 Overview 11
4 History 13
5 Competitors 16
6 Key Employees 17
7 Key Employee Biographies 19
8 Company Statement 21
9 Locations And Subsidiaries 23
9.1 Head Office 23
9.2 Other Locations & Subsidiaries 23
10 Recent Developments 25
10.1 Financial Announcements 25
10.1.1 Jul 23, 2008: Genzyme Reports 2Q 2008 Results 25
10.1.2 Apr 23, 2008: Genzyme Declares Q1 2008 Results 27
10.1.3 Feb 13, 2008: Genzyme Declares Q4 2007 Results 28
10.1.4 Oct 24, 2007: Genzyme Declares Q3 2007 Results 31
10.1.5 Jul 25, 2007: Genzyme Declares Q2 2007 Results 32
10.2 Legal and Regulatory 33
10.2.1 Aug 09, 2007: Genzyme Settles Lawsuit Brought By Shareholders 33
10.3 Product News 34
10.3.1 Apr 14, 2008: Genzyme Genetics Announces Launch Of Carrier Testing And Prenatal Diagnosis For Spinal Muscular Atrophy 34
10.3.2 Dec 19, 2007: Genzyme Receives European CE Mark For Single-Treatment Synvisc-One 34
10.3.3 Nov 13, 2007: Genzyme Corporation Receives FDA Response Letter On Synvisc-One Approval In US To Be Delayed 35
10.3.4 Nov 13, 2007: Genzyme Receives FDA Response Letter On Synvisc-One 35
10.3.5 Jul 05, 2007: Genzyme Announces Results Of Clinical Trial For Hylastan 35
10.3.6 Jul 05, 2007: Genzyme Arthritis Treatment Misses Goal In Pivotal Trial; Company Will Pursue Alternative Strategy 36
10.4 Product Approvals 36
10.4.1 Dec 19, 2007: Genzyme Receives European CE Mark For Single-Treatment Synvisc-One 36
10.5 Clinical Trials 36
10.5.1 Jul 05, 2007: Genzyme Announces Results Of Clinical Trial For Hylastan 36
10.5.2 Jul 05, 2007: Genzyme Arthritis Treatment Misses Goal In Pivotal Trial; Company Will Pursue Alternative Strategy 37
11 Genzyme Corporation Pipeline Products 38
11.1 Genzyme Corporation Product Pipeline Analysis 38
11.1.1 Genzyme Corporation Pipeline Products By Equipment Type 38
11.1.2 Genzyme Corporation Pipeline Products By Development Stage 41
11.1.3 Genzyme Corporation Pipeline Products By Therapy Area 42
11.1.4 Genzyme Corporation Pipeline Products By Clinical Trials 42
11.1.5 Genzyme Corporation Pipeline Products By News Summary 43
11.2 Synvisc-One 43
11.2.1 Product Description 44
11.2.2 Product Status 44
11.2.3 Clinical Trials 44
11.2.4 Product Milestone 46
11.3 Next Generation Synvisc (hylan G-F 20) 46
11.3.1 Product Description 46
11.3.2 Product Status 46
11.3.3 Clinical Trials 47
11.3.4 Product Milestone 52
11.4 Carticel II 52
11.4.1 Product Description 52
11.4.2 Product Status 53
11.4.3 Clinical Trials 53
11.5 Hylastan 53
11.5.1 Product Description 54
11.5.2 Product Status 54
11.5.3 Clinical Trials 54
11.5.4 Product Milestone 55
11.6 Sepragel Ortho 56
11.6.1 Product Description 56
11.6.2 Product Status 56
11.7 Third generation cartilage repair 56
11.7.1 Product Description 56
11.7.2 Product Status 56
11.8 Sepraspray adhesion barrier 57
11.8.1 Product Description 57
11.8.2 Product Status 57
11.8.3 Clinical Trials 57
11.9 Novel tests for new targeted therapies in hematologic malignancy 59
11.9.1 Product Description 59
11.9.2 Product Status 60
11.10 Candida Rapid Test 60
11.10.1 Product Description 60
11.10.2 Product Status 60
11.11 CLIA waived Flu A & B rapid test 61
11.11.1 Product Description 61
11.11.2 Product Status 61
11.12 C. difficile toxin A & B rapid test 61
11.12.1 Product Description 61
11.12.2 Product Status 61
11.13 Adenovirus rapid test 62
11.13.1 Product Description 62
11.13.2 Product Status 62
11.14 Hemoglobin A1c-diabetes 62
11.14.1 Product Description 62
11.14.2 Product Status 63
11.15 KIM-1 -- renal 63
11.15.1 Product Description 63
11.15.2 Product Status 63
11.16 Cystatin C renal 63
11.16.1 Product Description 63
11.16.2 Product Status 63
12 Appendix 64
12.1 Methodology 64
12.1.1 Coverage 64
12.1.2 Secondary Research 65
12.1.3 Primary Research 65
12.1.4 Expert Panel Validation 66
12.2 Contact Us 66
12.3 About Global Markets Direct 66
12.4 Disclaimer 66

1.1 List of Tables
Table 1: Genzyme Corporation,Key Facts 9
Table 2: Genzyme Corporation, Key Employees, 17
Table 3: Genzyme Corporation, Subsidiaries 23
Table 4: Genzyme Corporation Pipeline Products by Equipment Type 40
Table 5: Genzyme Corporation Pipeline Products By Development Stage 41
Table 6: Genzyme Corporation Pipeline Products By Therapy Area 42
Table 7: Genzyme Corporation Pipeline Products By Clinical Trials 42
Table 8: Genzyme Corporation Pipeline Products By News Summaries 43

1.2 List of Figures
Figure 1: Genzyme Corporation Pipeline Products By Equipment Type 38
Figure 2: Genzyme Corporation Pipeline Products By Equipment Type 39
Figure 3: Genzyme Corporation Pipeline Products By Development Stage 41
Figure 4: Genzyme Corporation Pipeline Products By News Summary 43
Figure 5: Global Markets Direct Methodology 64